S. Tejpar

Publications324
h-index59
Citations21,225
Highly Influential Citations1,034
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Van Cutsem
  • 552 Publications, 74,202 Citations
  • S. Kopetz
  • 612 Publications, 20,476 Citations
  • P. Laurent-Puig
  • 601 Publications, 39,783 Citations
  • A. Bardelli
  • 400 Publications, 40,093 Citations
  • Publications
  • Influence
The Consensus Molecular Subtypes of Colorectal Cancer
Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and drug responses. To resolve inconsistencies among the reported gene expression–based CRC classifications and… Expand
  • 1,641
  • 158
  • PDF
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
BACKGROUND Following the discovery that mutant KRAS is associated with resistance to anti-epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic colorectal cancer… Expand
  • 1,682
  • 96
  • PDF
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
PURPOSE The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease… Expand
  • 1,478
  • 68
  • PDF
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC… Expand
  • 1,103
  • 68
  • PDF
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
PURPOSE Mutations within the KRAS proto-oncogene have predictive value but are of uncertain prognostic value in the treatment of advanced colorectal cancer. We took advantage of PETACC-3, an adjuvant… Expand
  • 904
  • 48
Guidelines for the clinical management of familial adenomatous polyposis (FAP)
Background: Familial adenomatous polyposis (FAP) is a well-described inherited syndrome, which is responsible for <1% of all colorectal cancer (CRC) cases. The syndrome is characterised by the… Expand
  • 523
  • 36
  • PDF
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
CONTEXT Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor… Expand
  • 614
  • 25
  • PDF
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
PURPOSE The phase III CRYSTAL study demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival,… Expand
  • 438
  • 24
  • PDF
Peutz–Jeghers syndrome: a systematic review and recommendations for management
Peutz–Jeghers syndrome (PJS, MIM175200) is an autosomal dominant condition defined by the development of characteristic polyps throughout the gastrointestinal tract and mucocutaneous pigmentation.… Expand
  • 477
  • 22
  • PDF
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.
An international panel of multidisciplinary experts convened to develop recommendations for managing patients with colorectal cancer (CRC) and synchronous liver metastases (CRCLM). A modified Delphi… Expand
  • 201
  • 22
  • PDF